NL300415I2 - - Google Patents

Download PDF

Info

Publication number
NL300415I2
NL300415I2 NL300415C NL300415C NL300415I2 NL 300415 I2 NL300415 I2 NL 300415I2 NL 300415 C NL300415 C NL 300415C NL 300415 C NL300415 C NL 300415C NL 300415 I2 NL300415 I2 NL 300415I2
Authority
NL
Netherlands
Application number
NL300415C
Other languages
Dutch (nl)
Other versions
NL300415I1 (nl
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906437.0A external-priority patent/GB9906437D0/en
Priority claimed from GBGB9909077.1A external-priority patent/GB9909077D0/en
Priority claimed from GBGB9909466.6A external-priority patent/GB9909466D0/en
Priority claimed from GBGB9916677.9A external-priority patent/GB9916677D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of NL300415I1 publication Critical patent/NL300415I1/nl
Publication of NL300415I2 publication Critical patent/NL300415I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL300415C 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn NL300415I1 (nl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9906437.0A GB9906437D0 (en) 1999-03-19 1999-03-19 Vaccine
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions
GBGB9909466.6A GB9909466D0 (en) 1999-04-23 1999-04-23 Vaccines
GBGB9916677.9A GB9916677D0 (en) 1999-07-15 1999-07-15 Vaccine
PCT/EP2000/002468 WO2000056360A2 (en) 1999-03-19 2000-03-17 Vaccine against antigens from bacteriae

Publications (2)

Publication Number Publication Date
NL300415I1 NL300415I1 (nl) 2009-12-01
NL300415I2 true NL300415I2 (forum.php) 2016-12-13

Family

ID=27451884

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300415C NL300415I1 (nl) 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn

Country Status (32)

Country Link
US (8) US20030147922A1 (forum.php)
EP (6) EP1162998B1 (forum.php)
JP (4) JP4846906B2 (forum.php)
KR (3) KR20020000785A (forum.php)
CN (3) CN1192798C (forum.php)
AR (3) AR022964A1 (forum.php)
AT (3) ATE346608T1 (forum.php)
AU (3) AU750762B2 (forum.php)
BE (1) BE1025464I2 (forum.php)
BR (4) BR0009163A (forum.php)
CA (3) CA2366152A1 (forum.php)
CY (3) CY1107561T1 (forum.php)
CZ (3) CZ301445B6 (forum.php)
DE (4) DE60043930D1 (forum.php)
DK (2) DK1163000T3 (forum.php)
ES (3) ES2300255T3 (forum.php)
FR (1) FR10C0008I2 (forum.php)
HK (3) HK1043730A1 (forum.php)
HU (4) HU228499B1 (forum.php)
IL (5) IL145043A0 (forum.php)
LU (1) LU91652I2 (forum.php)
MX (1) MXPA01009452A (forum.php)
MY (2) MY125387A (forum.php)
NL (1) NL300415I1 (forum.php)
NO (4) NO20014322L (forum.php)
NZ (3) NZ513841A (forum.php)
PL (3) PL355178A1 (forum.php)
PT (2) PT1162999E (forum.php)
SI (2) SI1162999T1 (forum.php)
TR (3) TR200102736T2 (forum.php)
TW (3) TWI235064B (forum.php)
WO (3) WO2000056358A2 (forum.php)

Families Citing this family (289)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
ES2283012T3 (es) 1996-01-04 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Bacterioferritina de helicobacter pylori.
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US20010016200A1 (en) 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
AU761899B2 (en) 1998-05-22 2003-06-12 Ottawa Health Research Institute Methods and products for inducing mucosal immunity
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
CN1192798C (zh) 1999-03-19 2005-03-16 史åƆäøå…‹čŽ±ę©ęƔ彻姆ē”Ÿē‰©ęœ‰é™å…¬åø ē–«č‹—
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
WO2002034771A2 (en) 2000-10-27 2002-05-02 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
PT2332581E (pt) 2001-01-23 2015-10-16 Sanofi Pasteur Inc Vacina meningocĆ³cica tri- ou tetravalente de conjugados de polissacĆ”rido e crm-197
DK1361890T3 (da) 2001-02-23 2011-06-27 Glaxosmithkline Biolog Sa Influenzavaccineformuleringer til intradermal indgift
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
RU2331435C2 (ru) 2001-12-12 2008-08-20 Š§ŠøрŠ¾Š½ Š”рŠ». Š˜Š¼Š¼ŃƒŠ½ŠøŠ·Š°Ń†Šøя ŠæрŠ¾Ń‚ŠøŠ² chlamydia trachomatis
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
JP4646516B2 (ja) 2002-02-20 2011-03-09 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ 惐ć‚Æć‚·ćƒ³ć‚ŗ ć‚¢ćƒ³ćƒ‰ ćƒ€ć‚¤ć‚¢ć‚°ćƒŽć‚¹ćƒ†ć‚£ćƒƒć‚Æć‚¹ļ¼Œć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ćƒ¼ćƒ†ćƒƒćƒ‰ åøē€ć—ćŸćƒćƒŖćƒšćƒ—ćƒćƒ‰å«ęœ‰åˆ†å­ć‚’ęœ‰ć™ć‚‹å¾®ē²’子
RU2378008C2 (ru) * 2002-05-14 2010-01-10 ŠŠ¾Š²Š°Ń€Ń‚Šøс Š’эŠŗсŠøŠ½ŠµŃ Š­Š½Š“ Š”Š°Š¹ŃŠ³Š½Š¾ŃŃ‚ŠøŠŗс Š”.Š .Š›. ŠšŠ¾Š¼Š±ŠøŠ½ŠøрŠ¾Š²Š°Š½Š½Ń‹Šµ Š²Š°ŠŗцŠøŠ½Ń‹ ŠæрŠ¾Ń‚ŠøŠ² Š±Š°ŠŗтŠµŃ€ŠøŠ°Š»ŃŒŠ½Š¾Š³Š¾ Š¼ŠµŠ½ŠøŠ½Š³ŠøтŠ° Š“Š»Ń Š²Š²ŠµŠ“ŠµŠ½Šøя чŠµŃ€ŠµŠ· сŠ»ŠøŠ·Šøстую Š¾Š±Š¾Š»Š¾Ń‡Šŗу
DE60328481D1 (de) * 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthƤlt
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
AU2003274511B2 (en) 2002-10-11 2009-06-04 Glaxosmithkline Biologicals S.A. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
JP5116971B2 (ja) * 2002-10-15 2013-01-09 ć‚¤ćƒ³ć‚æćƒ¼ć‚»ćƒ« ć‚¢ćƒ¼ć‚²ćƒ¼ ļ¼¢ē¾¤é€£éŽ–ēƒčŒć®ęŽ„ē€å› å­ć‚’ć‚³ćƒ¼ćƒ‰ć™ć‚‹ę øé…ø态ļ½‚ē¾¤é€£éŽ–ēƒčŒć®ęŽ„ē€å› å­ć€ćŠć‚ˆć³ćć®ä½æē”Ø
NZ539613A (en) 2002-11-01 2008-09-26 Glaxosmithkline Biolog Sa Drying process for biological samples
JP5814494B2 (ja) 2002-11-12 2015-11-17 悶 惖ćƒŖć‚¬ćƒ  ć‚¢ćƒ³ćƒ‰ ć‚¦ć‚£ćƒ”ćƒ³ć‚ŗ ćƒ›ć‚¹ćƒ”ć‚æ惫 ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ļ¼“ļ½ˆļ½… ļ¼¢ļ½’ļ½‰ļ½‡ļ½ˆļ½ļ½ ļ½ļ½Žļ½„ ļ¼·ļ½ļ½ļ½…ļ½Žā€™ļ½“ ļ¼Øļ½ļ½“ļ½ļ½‰ļ½”ļ½ļ½Œļ¼Œ ļ¼©ļ½Žļ½ƒļ¼Ž ļ¼³ļ½”ļ½ļ½ļ½ˆļ½™ļ½Œļ½ļ½ƒļ½ļ½ƒļ½ƒļ½•ļ½“ę„ŸęŸ“ć«åÆ¾ć™ć‚‹å¤šē³–锞ćƒÆć‚Æćƒćƒ³
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5ā€™ cpg nucleic acids and methods of use
CA2511512C (en) 2002-12-27 2013-10-29 Chiron Corporation Immunogenic compositions containing phospholipid
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
CA3042073C (en) 2003-01-30 2022-09-13 Novartis Vaccines And Diagnostics S.R.L. Injectable vaccines against multiple meningococcal serogroups
MXPA05009351A (es) * 2003-03-07 2006-03-08 Wyeth Corp Conjugados de polisacarido-proteina portadora adhesina superficial de estafilococo para inmunizacion contra infecciones nosocomiales.
WO2004081515A2 (en) * 2003-03-13 2004-09-23 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgĆ”nicos para la inmunopotenciaciĆ³n
WO2005020964A1 (en) 2003-06-02 2005-03-10 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
JP4738339B2 (ja) * 2003-10-02 2011-08-03 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ćƒ“ć‚”ć‚Æć‚·ćƒ³ć‚ŗ ć‚¢ćƒ³ćƒ‰ ćƒ€ć‚¤ć‚¢ć‚°ćƒŽć‚¹ćƒ†ć‚£ć‚Æć‚¹ ć‚Øć‚¹ć‚¢ćƒ¼ćƒ«ć‚Ø惫 č¤‡ę•°ć®é«„č†œē‚ŽčŒč”€ęø…ē¾¤ć«ć¤ć„ć¦ć®ę¶²ä½“ćƒÆć‚Æćƒćƒ³
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
WO2005105140A2 (en) 2004-04-30 2005-11-10 Chiron Srl Meningococcal conjugate vaccination
US7444197B2 (en) * 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
EP2277595A3 (en) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
WO2006078318A2 (en) 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
ES2616294T3 (es) 2005-01-27 2017-06-12 Children's Hospital & Research Center At Oakland Vacunas de vesĆ­culas basadas en GNA1870 para protecciĆ³n de amplio espectro contra enfermedades provocadas por Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
CN101180312A (zh) 2005-02-18 2008-05-14 čÆŗ华ē–«č‹—å’ŒčÆŠę–­å…¬åø ę„č‡Ŗå°æč·Æē—…åŽŸę€§å¤§č‚ ę†čŒēš„免ē–«åŽŸ
EP1858920B1 (en) 2005-02-18 2016-02-03 GlaxoSmithKline Biologicals SA Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
MX2007012336A (es) * 2005-04-08 2007-11-21 Wyeth Corp Composicion de conjugados de proteina-polisacaridos multivalentes par neumococos.
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP2329843A3 (en) 2005-04-18 2011-09-14 Novartis Vaccines and Diagnostics, Inc. Expressing Hepatitis B Virus surface antigen for vaccine preparation
DK2878307T3 (da) * 2005-06-27 2019-10-07 Glaxosmithkline Biologicals Sa Immunogen sammensƦtning
JP5135220B2 (ja) 2005-09-01 2013-02-06 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ćƒ“ć‚”ć‚Æć‚·ćƒ³ć‚ŗ ć‚¢ćƒ³ćƒ‰ ćƒ€ć‚¤ć‚¢ć‚°ćƒŽć‚¹ćƒ†ć‚£ć‚Æć‚¹ ć‚²ćƒ¼ć‚Øćƒ ćƒ™ćƒ¼ćƒćƒ¼ ć‚¢ćƒ³ćƒ‰ ć‚«ćƒ³ćƒ‘ćƒ‹ćƒ¼ ć‚«ćƒ¼ć‚²ćƒ¼ 蔀ęø…ē¾¤ļ½ƒé«„č†œē‚ŽčŒć‚’å«ć‚€č¤‡ę•°ćƒÆć‚Æćƒćƒ³ęŽ„ēØ®
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. PartĆ­culas similares a virus (VLPs) de Norovirus y Sapovirus
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa ꖰē©Žēµ„合ē‰©
AU2006327040B2 (en) * 2005-12-22 2010-08-19 Glaxosmithkline Biologicals Sa Vaccine comprising Streptococcus pneumoniae capsular polyaccharide conjugates
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
MY150105A (en) * 2006-01-17 2013-11-29 Forsgren Arne A novel surface exposed haemophilus influenzae protein (protein e; pe)
CN101024079B (zh) * 2006-02-17 2012-02-01 ē¦å·žę˜Œę™–ē”Ÿē‰©å·„ēØ‹ęœ‰é™å…¬åø č‚ŗē‚Žé“¾ēƒčŒå¤šē³–-å¤–č†œč›‹ē™½ē»“合ē–«č‹—åŠåˆ¶å¤‡ę–¹ę³•
KR101947794B1 (ko) * 2006-03-17 2019-02-13 ė” ź±°ė²„ėؼķŠø ģ˜¤ėøŒ ė” ģœ ė‚˜ģ“ķ‹°ė“œ ģŠ¤ķ…Œģ“ģø  ģ˜¤ėøŒ ģ•„ė©”ė¦¬ģ¹“ ģ—ģ¦ˆ ė ˆķ”„ė¦¬ģ  ķ‹°ė“œ ė°”ģ“ ė” ģ„øķ¬ėŸ¬ķ…Œė¦¬ ģ˜¤ėøŒ ė” ė””ķŒŒķŠøėؼķŠø ģ˜¤ėøŒ ķ—¬ģŠ¤ ģ•¤ė“œ ķœ“ėؼ ģ„œė¹„ģ‹œģ¦ˆ ė³µķ•© ė‹¤ź°€ ė©“ģ—­ģ›ģ„± ģ½˜ģ„¬ź²Œģ“ķŠøģ˜ ģ œģ”° ė°©ė²•
NZ572054A (en) 2006-03-22 2011-12-22 Novartis Ag Regimens for immunisation with meningococcal conjugates
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
KR101541383B1 (ko) * 2006-03-30 2015-08-03 źø€ė½ģ†ŒģŠ¤ėÆøģŠ¤ķ“ė¼ģø ė°”ģ“ģ˜¤ė”œģ§€ģ¹¼ģ¦ˆ ģ—ģŠ¤.ģ—ģ“. ė©“ģ—­ģ›ģ„± ģ”°ģ„±ė¬¼
TWI494124B (zh) * 2006-03-30 2015-08-01 Glaxosmithkline Biolog Sa 免ē–«åŽŸēµ„合ē‰©
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
EP2054431B1 (en) * 2006-06-09 2011-08-31 Novartis AG Conformers of bacterial adhesins
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
JP2010500399A (ja) 2006-08-16 2010-01-07 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ å°æč·Æē—…åŽŸę€§å¤§č…ø菌ē”±ę„ć®å…ē–«åŽŸ
CN102648979B (zh) * 2006-10-10 2014-05-14 ęƒ ę°å…¬åø č‚ŗē‚Žé“¾ēƒčŒ3型多ē³–ēš„ēŗÆ化
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
JP2010531330A (ja) 2007-06-26 2010-09-24 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  č‚ŗē‚Žé€£éŽ–ēƒčŒčŽ¢č†œå¤šē³–ć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆć‚’å«ć‚€ćƒÆć‚Æćƒćƒ³
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
ES2561483T3 (es) 2007-09-12 2016-02-26 Glaxosmithkline Biologicals Sa AntĆ­genos mutantes de GAS57 y anticuerpos de GAS57
EP2200642B1 (en) 2007-10-19 2012-04-18 Novartis AG Meningococcal vaccine formulations
US20090124573A1 (en) 2007-11-09 2009-05-14 Sarkis Mazmanian Immunomodulating compounds and related compositions and methods
EP3067048B1 (en) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EP2235046B1 (en) 2007-12-21 2012-08-01 Novartis AG Mutant forms of streptolysin o
AU2009208403A1 (en) * 2008-02-01 2009-08-06 Newcastle Innovation Limited Vaccine compositions
AU2009215364B2 (en) 2008-02-21 2014-09-18 Glaxosmithkline Biologicals S.A. Meningococcal fHBP polypeptides
CA2717870A1 (en) 2008-03-10 2009-09-17 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
CN105085349B (zh) 2008-07-21 2018-02-09 åøƒčµ–ę±‰å§†å¦‡å„³åŒ»é™¢ äøŽåˆęˆēš„Ī²ā€‘1,6 č‘”ē³–čƒŗåÆ”ē³–ē›ø关ēš„ę–¹ę³•å’Œē»„合ē‰©
AU2009309416B2 (en) 2008-10-27 2015-05-28 Glaxosmithkline Biologicals S.A. Purification method
BRPI0922561A2 (pt) 2008-12-09 2020-08-11 Pfizer Vaccines Llc vacina de peptĆ­deo de ch3 da ige.
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
CA2747340A1 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
EP2384120B1 (en) 2009-01-05 2019-12-11 Epitogenesis Inc. Adjuvant compositions and methods of use
US8465751B2 (en) 2009-01-12 2013-06-18 Novartis Ag Cnaā€”B domain antigens in vaccines against gram positive bacteria
CN102427826B (zh) 2009-03-24 2014-11-26 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø äøŗ脑膜ē‚ŽēƒčŒå› å­hē»“åˆč›‹ē™½ę·»åŠ ä½å‰‚
EP2411045A1 (en) 2009-03-24 2012-02-01 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
EP2419129A2 (en) 2009-04-14 2012-02-22 Novartis AG Compositions for immunising against staphylococcus aerus
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
CN102481352A (zh) 2009-06-22 2012-05-30 ęƒ ę°ęœ‰é™č“£ä»»å…¬åø é‡‘é»„č‰²č‘”č„ēƒčŒęŠ—原ēš„免ē–«åŽŸę€§ē»„合ē‰©
SG10201406432RA (en) 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
US8647621B2 (en) 2009-07-27 2014-02-11 Fina Biosolutions, Llc Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
AU2010277254B2 (en) 2009-07-30 2015-05-07 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
NZ598458A (en) 2009-08-27 2014-03-28 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
KR101512053B1 (ko) 2009-09-03 2015-04-28 ķ™”ģ“ģž ė°±ģ‹ ģŠ¤ ģ—˜ģ—˜ģ”Ø ļ¼°ļ½ƒļ½“ļ½‹ļ¼™ ė°±ģ‹ 
CN102695523A (zh) 2009-09-10 2012-09-26 čÆŗåŽęœ‰é™å…¬åø 针åƹ呼åø道ē–¾ē—…ēš„ē»„合ē–«č‹—
US20130022633A1 (en) 2009-10-27 2013-01-24 University Of Florence MENINGOCOCCAL fHBP POLYPEPTIDES
BR112012010223A2 (pt) 2009-10-30 2016-12-06 Novartis Ag purificaĆ§Ć£o de staphylococcus aureus tipo 5 e tipo 8 sacarĆ­deos capsulares
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
BR112012014882B1 (pt) 2009-12-17 2022-05-31 Fina Biosolutions, Llc Processo de conjugaĆ§Ć£o de carboidratos na preparaĆ§Ć£o de vacinas conjugadas e suas respectivas vacinas ou agentes diagnĆ³sticos
CN107412754A (zh) 2009-12-22 2017-12-01 唞尔德克ę–Æ医ē–—å…¬åø ē–«č‹—ē»„合ē‰©
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
ES2977505T3 (es) 2010-03-30 2024-08-26 Childrens Hospital & Res Center At Oakland ProteĆ­nas de uniĆ³n al factor H (fHbp) con propiedades alteradas y mĆ©todos de uso de las mismas
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
ES2694100T3 (es) 2010-04-07 2018-12-18 California Institute Of Technology VehĆ­culo para distribuir un compuesto en una membrana mucosa y composiciones, procedimientos y sistemas relacionados
CA2800174A1 (en) * 2010-05-20 2011-11-24 June L. Round Antigen specific tregs and related compositions, methods and systems
EP2575988A1 (en) 2010-05-28 2013-04-10 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
WO2011151760A2 (en) * 2010-06-04 2011-12-08 Wyeth Llc Vaccine formulations
EP2942061A3 (en) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
WO2011154863A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
CA2860331A1 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
JP6191082B2 (ja) 2011-03-02 2017-09-06 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  ć‚ˆć‚Šä½Žē”Øé‡ć®ęŠ—åŽŸćŠć‚ˆć³ļ¼ć¾ćŸćÆć‚¢ć‚øćƒ„ćƒćƒ³ćƒˆć‚’ęœ‰ć™ć‚‹ę··åˆćƒÆć‚Æćƒćƒ³
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
ES2785108T3 (es) 2011-03-24 2020-10-05 Glaxosmithkline Biologicals Sa Nanoemulsiones adyuvantes con fosfolĆ­pidos
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
EP2705853B1 (en) 2011-05-06 2018-07-18 Aparin, Petr Gennadievich Exopolysaccharide of shigella sonnei bacteria, method for producing same, vaccine and pharmaceutical composition containing same
AU2012272652B2 (en) 2011-06-24 2017-06-01 Epitogenesis Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
US9149541B2 (en) 2011-07-08 2015-10-06 Novartis Ag Tyrosine ligation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
US20140235667A1 (en) 2011-09-22 2014-08-21 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
EP2776069A1 (en) 2011-11-07 2014-09-17 Novartis AG Carrier molecule comprising a spr0096 and a spr2021 antigen
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
ES2704069T3 (es) 2011-12-08 2019-03-14 Glaxosmithkline Biologicals Sa Vacuna basada en toxinas de Clostridium difficile
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
WO2013098589A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
RU2014138418A (ru) 2012-02-24 2016-04-10 ŠŠ¾Š²Š°Ń€Ń‚Šøс ŠŠ³ Š‘ŠµŠ»ŠŗŠø ŠæŠøŠ»ŠµŠ¹ Šø ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø
EP2822586A1 (en) 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of streptococcus pneumoniae antigens
WO2013132043A1 (en) 2012-03-08 2013-09-12 Novartis Ag Combination vaccines with tlr4 agonists
SA115360586B1 (ar) 2012-03-09 2017-04-12 ŁŲ§ŁŠŲ²Ų± Ų§Ł†Łƒ ŲŖŲ±ŁƒŁŠŲØŲ§ŲŖ Ł„Ų¹Ł„Ų§Ų¬ Ų§Ł„Ų§Ł„ŲŖŁ‡Ų§ŲØ Ų§Ł„Ų³Ų­Ų§Ų¦ŁŠ Ų§Ł„ŲØŁƒŲŖŁŠŲ±ŁŠ ŁˆŲ·Ų±Ł‚ Ł„ŲŖŲ­Ų¶ŁŠŲ±Ł‡Ų§
AU2013254751B2 (en) 2012-04-26 2017-12-14 Glaxosmithkline Biologicals S.A. Antigens and antigen combinations
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
AU2013255511B2 (en) 2012-05-04 2016-01-28 Pfizer Inc. Prostate-associated antigens and vaccine-based immunotherapy regimens
BR112014029313A2 (pt) 2012-05-22 2017-06-27 Novartis Ag conjugado de meningococos do sorogrupo x
KR102057217B1 (ko) 2012-06-20 2020-01-22 ģ—ģŠ¤ģ¼€ģ“ė°”ģ“ģ˜¤ģ‚¬ģ“ģ–øģŠ¤ ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
WO2014037472A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
MX2015002482A (es) 2012-10-03 2016-01-08 Glaxosmithkline Biolog Sa Composicion inmunogenica.
BR112015008040A2 (pt) 2012-10-12 2017-07-04 Glaxosmithkline Biologicals Sa composiĆ§Ć£o de vacina, vacina de combinaĆ§Ć£o, e, processos para preparar um componente ap e para a fabricaĆ§Ć£o de uma composiĆ§Ć£o de vacina
BR112015008418A2 (pt) * 2012-10-17 2017-07-04 Glaxosmithkline Biologicals Sa uso de uma composiĆ§Ć£o imunogĆŖnica, composiĆ§Ć£o imunogĆŖnica, e, mĆ©todos para intensificar atividade opsĆ“nica mediada por anticorpo contra um sorotipo alvejado de streptococcus pneumoniae em um indivĆ­duo e para imunizar um hospedeiro humano contra doenƧas causadas por infecĆ§Ć£o por streptococcus pneumoniae
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
KR20140075201A (ko) * 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
KR20140075196A (ko) 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
CA2911826C (en) 2013-05-10 2022-08-23 California Institute Of Technology Probiotic prevention and treatment of colon cancer
AU2014385320B2 (en) 2013-05-15 2019-10-10 The Governors Of The University Of Alberta E1E2 HCV vaccines and methods of use
CN103386126B (zh) * 2013-06-25 2015-06-17 北äŗ¬ē§‘å…“ē”Ÿē‰©åˆ¶å“ęœ‰é™å…¬åø äø€ē§å«č‚ é“ē—…ęÆ’ęŠ—åŽŸēš„多价免ē–«åŽŸę€§ē»„合ē‰©
KR20180099912A (ko) 2013-09-08 2018-09-05 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ė‚˜ģ“ģ„øė¦¬ģ•„ ė©”ė‹Œģ§€ķ‹°ė””ģŠ¤ ģ”°ģ„±ė¬¼ ė° ź·øģ˜ ė°©ė²•
WO2015095868A1 (en) * 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
PL3096783T3 (pl) * 2014-01-21 2021-12-13 Pfizer Inc. Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty
HUE051728T2 (hu) 2014-01-21 2021-03-29 Pfizer KonjugĆ”lt burokszaccharid antigĆ©neket tartalmazĆ³ immunogĆ©n kĆ©szĆ­tmĆ©nyek Ć©s alkalmazĆ”saik
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
SI3110442T1 (sl) 2014-02-28 2021-01-29 Glaxosmithkline Biologicals S.A. Modificirani meningokokni fHbp polipeptidi
EP2921856B1 (en) * 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
CN104829711B (zh) * 2014-04-08 2018-04-03 北äŗ¬å¤©ęˆę–°č„‰ē”Ÿē‰©ęŠ€ęœÆęœ‰é™å…¬åø 脑膜ē‚ŽēƒčŒčšč†œå¤šē³–å•å…‹éš†ęŠ—ä½“åŠå…¶åŗ”ē”Ø
CR20170020A (es) 2014-07-23 2017-08-10 ChildrenĀ“S Hospital & Res Center At Oakland Variantes de proteĆ­nas de uniĆ³n al factor h y mĆ©todos de uso de estas
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
AU2016207820B2 (en) 2015-01-15 2020-12-17 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN104548090B (zh) * 2015-01-27 2016-11-30 äø­å›½ē§‘学院čæ‡ēØ‹å·„ē؋ē ”ē©¶ę‰€ äø€ē§Ī²-葔聚ē³–äæ®é„°ēš„č„‘č†œē‚Žå¤šē³–ē»“合ē–«č‹—åŠå…¶åˆ¶å¤‡ę–¹ę³•
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
CN107849119A (zh) 2015-07-07 2018-03-27 é˜æč“¹é‡Œę–Æč‚”ä»½å…¬åø ē”ØäŗŽę²»ē–—和预防IgE介åƼēš„ē–¾ē—…ēš„ē–«č‹—
CN108367063A (zh) 2015-07-21 2018-08-03 č¾‰ē‘žå…¬åø 包含ē¼€åˆēš„čšč†œē³–ęŠ—åŽŸēš„免ē–«åŽŸę€§ē»„合ē‰©åŠå…¶čƕ剂ē›’å’Œē”Ø途
US11065283B2 (en) 2015-08-25 2021-07-20 Babita Agrawal Immunomodulatory compositions and methods of use thereof
AU2016336150B2 (en) 2015-10-08 2023-08-10 The Governors Of The University Of Alberta Hepatitis C virus E1/E2 heterodimers and methods of producing same
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
BR112018010705A8 (pt) 2015-12-04 2019-02-26 Dana Farber Cancer Inst Inc vacinaĆ§Ć£o com o domĆ­nio mica/b alfa 3 para o tratamento de cĆ¢ncer
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
KR102158923B1 (ko) 2016-01-19 2020-09-23 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ģ•” ė°±ģ‹ 
US11612664B2 (en) 2016-04-05 2023-03-28 Gsk Vaccines S.R.L. Immunogenic compositions
EP3474890A1 (en) 2016-06-22 2019-05-01 Max-Planck-Gesellschaft zur Fƶrderung der Wissenschaften E. V. Pneumococcal polysaccharide-protein conjugate composition
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
SG11201900794PA (en) 2016-08-05 2019-02-27 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
SG11201900789VA (en) 2016-08-05 2019-02-27 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
US12109259B2 (en) 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
CN110022894B (zh) 2016-10-07 2024-01-19 ꁩē‰¹ē½—姆公åø ē”ØäŗŽē™Œē—‡ē–—ę³•ēš„免ē–«åŽŸę€§åŒ–合ē‰©
KR102622188B1 (ko) 2016-10-07 2024-01-05 ģ—”ķ„°ė”¬ ģ—ģŠ¤.ģ—ģ“. ģ•” ģ¹˜ė£Œė„¼ ģœ„ķ•œ ė©“ģ—­ģ›ģ„± ķ™”ķ•©ė¬¼
US20210108002A1 (en) 2016-12-06 2021-04-15 Glaxosmithkline Biologicals Sa Purification Process For Capsular Polysaccharide
EP3570879B1 (en) 2017-01-20 2022-03-30 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN110520154B (zh) * 2017-03-15 2023-08-04 ę Ŗ式会ē¤¾Lg化学 多价č‚ŗē‚Žé“¾ēƒčŒē–«č‹—ē»„合ē‰©
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
CN110662557A (zh) 2017-03-31 2020-01-07 č‘›å…°ē“ å²å…‹ēŸ„čƆäŗ§ęƒå¼€å‘ęœ‰é™å…¬åø 免ē–«åŽŸę€§ē»„合ē‰©ć€ē”Øé€”å’Œę²»ē–—ę–¹ę³•
MX2019014829A (es) 2017-06-10 2020-08-17 Inventprise Llc Vacunas de conjugado multivalente con polisacƔridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas.
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
EP3641808A1 (en) 2017-08-14 2020-04-29 GlaxoSmithKline Biologicals S.A. Methods of boosting immune responses
US12257295B2 (en) 2017-10-04 2025-03-25 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
CR20200245A (es) 2017-12-06 2020-07-17 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacƔrido de streptococcus pneumoniae con proteƭna y mƩtodos de uso de estos
MX2020008198A (es) 2018-02-05 2020-09-22 Sanofi Pasteur Inc Composicion del conjugado proteina-polisacarido multivalente neumococica.
AU2019215212B2 (en) 2018-02-05 2025-05-15 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
WO2019197563A2 (en) 2018-04-11 2019-10-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
CN120535570A (zh) 2018-04-11 2025-08-26 ꁩē‰¹ē½—姆公åø ē”ØäŗŽé¢„é˜²å’Œę²»ē–—ē™Œē—‡ēš„ęŠ—åŽŸč‚½
KR20190121713A (ko) 2018-04-18 2019-10-28 ģ—ģŠ¤ģ¼€ģ“ė°”ģ“ģ˜¤ģ‚¬ģ“ģ–øģŠ¤(ģ£¼) ģŠ¤ķŠøė ™ķ† ģ½”ģ»¤ģŠ¤ ė‰“ėŖØė‹ˆģ•  ķ˜‘ė§‰ ė‹¤ė‹¹ė„˜ ė° ź·øģ˜ ė©“ģ—­ģ›ģ„± ģ ‘ķ•©ģ²“
CN112673054A (zh) 2018-07-19 2021-04-16 č‘›å…°ē“ å²åƆäøå…‹čŽ±ę©ē”Ÿē‰©ęœ‰é™å…¬åø ē”ØäŗŽåˆ¶å¤‡å¹²ē‡„多ē³–ēš„ę–¹ę³•
BR112021000965A2 (pt) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
EP3893926A1 (en) 2018-12-12 2021-10-20 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
WO2020120569A2 (en) 2018-12-12 2020-06-18 Glaxosmithkline Biologicals Sa Modified carrier proteins for o-linked glycosylation
JP7275277B2 (ja) 2018-12-19 2023-05-17 惔惫ć‚Æćƒ»ć‚·ćƒ£ćƒ¼ćƒ—ćƒ»ć‚¢ćƒ³ćƒ‰ćƒ»ćƒ‰ćƒ¼ćƒ ćƒ»ć‚Ø惫ć‚Øćƒ«ć‚·ćƒ¼ ć‚¹ćƒˆćƒ¬ćƒ—ćƒˆć‚³ćƒƒć‚«ć‚¹ćƒ»ćƒ‹ćƒ„ćƒ¼ćƒ¢ćƒ‹ć‚Ø多ē³–ļ¼ć‚æćƒ³ćƒ‘ć‚Æč³Ŗć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆć‚’å«ć‚€ēµ„ęˆē‰©ćŠć‚ˆć³ćć®ä½æē”Øę–¹ę³•
EP3908669A4 (en) 2019-01-11 2023-05-03 Northwestern University SYNTHESIS OF BIOCONJUGATED VACCINES IN PROKARYOT CELL LYSATE
WO2020163512A1 (en) 2019-02-05 2020-08-13 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
EP3923982A1 (en) 2019-02-11 2021-12-22 Pfizer Inc. Neisseria meningitidiscompositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ē“°čŒå¤šē³–锞悒ē²¾č£½ć™ć‚‹ćŸć‚ć®ę–¹ę³•
EP3952906A1 (en) 2019-04-10 2022-02-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3956666A1 (en) 2019-04-18 2022-02-23 GlaxoSmithKline Biologicals S.A. Antigen binding proteins and assays
JP2022532142A (ja) 2019-05-10 2022-07-13 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  ć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆć®č£½é€ 
US20230066762A1 (en) 2019-08-05 2023-03-02 Glaxosmithkline Biologicals Sa Immunogenic composition
CA3148928A1 (en) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein d polypeptide
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
MX2022004598A (es) 2019-10-16 2022-09-23 Enterome S A Compuestos inmunogenicos para el tratamiento del cancer suprarrenal.
MX2022005252A (es) 2019-11-01 2022-06-08 Pfizer Composiciones de escherichia coli y metodos de las mismas.
EP4357356A3 (en) 2019-11-15 2024-07-31 Enterome S.A. Antigenic peptides for prevention and treatment of b-cell malignancy
WO2021099982A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
WO2021138495A1 (en) * 2019-12-30 2021-07-08 Fraunhofer Usa, Inc. Particles for multi-dose delivery
WO2021165847A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
MX2022010350A (es) 2020-02-23 2022-09-19 Pfizer Composiciones de esquerichia coli y sus metodos.
CN111588847B (zh) * 2020-05-18 2023-05-26 å¹æ州äø­åŒ»čÆ大学(å¹æ州äø­åŒ»čÆē ”ē©¶é™¢) äø€ē§å«ęœ‰å•ē£·é…ø化ēš„č„‚č“ØaäøŽē³–ęŠ—åŽŸēš„ē¼€åˆē‰©åŠå…¶åˆ¶å¤‡ę–¹ę³•å’Œåŗ”ē”Ø
WO2021250626A2 (en) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Dock tag system
CA3191005A1 (en) 2020-08-10 2022-02-17 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
CA3199610A1 (en) 2020-10-27 2022-05-05 Pfizer Inc. Escherichia coli compositions and methods thereof
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
IL302413A (en) 2020-11-04 2023-06-01 Pfizer Immunogenic preparations for use in pneumococcal vaccines
WO2022101745A2 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
IL305313A (en) 2021-02-19 2023-10-01 Sanofi Pasteur Meningococcal b recombinant vaccine
EP4294433A1 (en) 2021-02-22 2023-12-27 GlaxoSmithKline Biologicals SA Immunogenic composition, use and methods
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
CA3221074A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20220387576A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3237496A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
AU2023246941A1 (en) 2022-03-31 2024-10-24 Enterome S.A. Antigenic peptides for prevention and treatment of cancer.
IL316477A (en) 2022-05-11 2024-12-01 Pfizer Process for producing vaccine formulations with preservatives
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
KR20250107930A (ko) 2022-11-22 2025-07-14 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ģ ‘ķ•©ėœ ķ”¼ė§‰ ģ‚¬ģ¹“ė¼ģ“ė“œ ķ•­ģ›ģ„ ķ¬ķ•Øķ•˜ėŠ” ė©“ģ—­ģ›ģ„± ģ”°ģ„±ė¬¼ ė° ź·øģ˜ ģš©ė„
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024246082A1 (en) 2023-03-30 2025-10-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025109417A1 (en) 2023-11-21 2025-05-30 Panacea Biotec Limited Immunogenic composition of haemophilus influenzae conjugated to protein d
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
CN120404993B (zh) * 2025-07-03 2025-10-03 ęˆéƒ½čæˆē§‘åŗ·ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø äø€ē§ę£€ęµ‹ę ·ęœ¬äø­mplēš„ę–¹ę³•åŠå…¶ē›ø关åŗ”ē”Ø

Family Cites Families (58)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0449856B1 (en) * 1988-12-16 2001-09-12 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
RU2118164C1 (ru) 1992-06-25 1998-08-27 Š”Š¼ŠøтŠŗŠ»Š°Š¹Š½ Š‘ŠøчŠ°Š¼ Š‘Š°Š¹Š¾Š»Š¾Š“Š¶ŠøŠŗŠ°Š»Ń, Š”.Š. Š’Š°ŠŗцŠøŠ½Š½Š°Ń ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøя, Š¾Š±Š»Š°Š“Š°ŃŽŃ‰Š°Ń сŠ²Š¾Š¹ŃŃ‚Š²Š¾Š¼ Š²Ń‹Š·Ń‹Š²Š°Ń‚ŃŒ цŠøтŠ¾Š»ŠøтŠøчŠµŃŠŗŠøŠ¹ т-ŠŗŠ»ŠµŃ‚Š¾Ń‡Š½Ń‹Š¹ Š¾Ń‚Š²ŠµŃ‚ у Š¼Š»ŠµŠŗŠ¾ŠæŠøтŠ°ŃŽŃ‰Šøх, сŠæŠ¾ŃŠ¾Š± ŠæŠ¾Š»ŃƒŃ‡ŠµŠ½Šøя цŠøтŠ¾Š»ŠøтŠøчŠµŃŠŗŠ¾Š³Š¾ т-ŠŗŠ»ŠµŃ‚Š¾Ń‡Š½Š¾Š³Š¾ Š¾Ń‚Š²ŠµŃ‚Š° in vivo, сŠæŠ¾ŃŠ¾Š± ŠæŠ¾Š»ŃƒŃ‡ŠµŠ½Šøя Š²Š°ŠŗцŠøŠ½Ń‹
DK0618813T3 (da) * 1992-09-16 2002-03-11 Univ Tennessee Res Corp Antigen for M-hybridprotein og bƦrer for gruppe A streptococcal vaccine
ES2109685T5 (es) 1993-03-23 2005-09-01 Smithkline Beecham Biologicals S.A. Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado.
JP3429313B2 (ja) 1993-05-18 2003-07-22 ć‚Ŗ惏悤ć‚Ŗćƒ»ć‚¹ćƒ†ć‚¤ćƒˆćƒ»ćƒŖć‚µćƒ¼ćƒćƒ»ćƒ•ć‚”ć‚¦ćƒ³ćƒ‡ćƒ¼ć‚·ćƒ§ćƒ³ äø­č€³ē‚ŽćƒÆć‚Æćƒćƒ³
KR100376361B1 (ko) 1993-09-22 2003-07-18 ķ—Øė¦¬ ģ— . ģž­ģŠØ ķŒŒģš“ė°ģ“ģ…˜ ķ¬ ė” ģ–“ė“œė²¤ģŠ¤ėؼķŠø ģ˜¤ėøŒ ė°€ė¦¬ķ„°ė¦¬ ė©”ė””ģ‹  ė©“ģ—­ģ›ģ„±źµ¬ģ”°ģ²“ģ˜ģ œģ”°ė„¼ģœ„ķ•˜ģ—¬ģ‹ ź·œķ•œģ‹œģ•„ė‹ė ˆģ“ķŒ…ģ‹œģ•½ģ„ģ‚¬ģš©ķ•˜ģ—¬ģš©ķ•“ģ„±ķƒ„ģˆ˜ķ™”ė¬¼ģ„ķ™œģ„±ķ™”ķ•˜ėŠ”ė°©ė²•
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
ES2267100T5 (es) 1994-07-15 2011-04-08 The University Of Iowa Research Foundation OligonucleĆ³tidos inmunomoduladores.
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
KR19990007858A (ko) * 1995-04-17 1999-01-25 ģ”“ ė”ėø”ģœ .ė”œģš° ė°•ķ…Œė¦¬ģ•„ģ˜ ė¦¬ķ¬ķ”„ė”œķ…Œģøģœ¼ė”œ ķ“ė¦¬ģ‚¬ģ¹“ė¼ģ“ė“œģ— ėŒ€ķ•œ ė©“ģ—­ė°˜ģ‘ģ˜ ģœ ė„ė° ź°•ķ™”
UA56132C2 (uk) * 1995-04-25 2003-05-15 Š”Š¼Ń–Ń‚ŠŗŠ»Š°Š¹Š½ Š‘ічŠµŠ¼ Š‘Š°Š¹Š¾Š»Š¾Š“Š¶Ń–ŠŗŠ°Š»Ń Š”.Š. ŠšŠ¾Š¼ŠæŠ¾Š·Šøція Š²Š°ŠŗцŠøŠ½Šø (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± стŠ°Š±Ń–Š»Ń–Š·Š°Ń†Ń–Ń— qs21 Š²Ń–Š“Š½Š¾ŃŠ½Š¾ Š³Ń–Š“рŠ¾Š»Ń–Š·Ńƒ (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± ŠæрŠøŠ³Š¾Ń‚ŃƒŠ²Š°Š½Š½Ń ŠŗŠ¾Š¼ŠæŠ¾Š·Šøції Š²Š°ŠŗцŠøŠ½Šø
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
EP0831901B2 (en) 1995-06-07 2005-12-07 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein
WO1996040928A1 (en) 1995-06-07 1996-12-19 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the hsp70 family
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
ES2262177T3 (es) 1996-05-01 2006-11-16 The Rockefeller University Proteinas de union a colina para vacunas frente a neumococos.
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JPH102001A (ja) * 1996-06-15 1998-01-06 Okajima Kogyo Kk ć‚°ćƒ¬ćƒ¼ćƒćƒ³ć‚°
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
WO1998055606A2 (en) 1997-06-03 1998-12-10 Connaught Laboratories Limited Lactoferrin receptor genes of moraxella
EP0998557A2 (en) 1997-07-21 2000-05-10 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
US6709658B1 (en) * 1998-02-12 2004-03-23 Wyeth Holdings Corporation Pneumococcal vaccines formulated with interleukin-12
KR100794394B1 (ko) 1998-04-07 2008-01-15 ė©”ė””ė®Ø ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ė°±ģ‹ ģš© ķė “ źµ¬ź· ģ˜ ģ½œė¦° ź²°ķ•©ģ„± ė‹Øė°±ģ§ˆģ˜ ģœ ė„ģ²“
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
CA2340692A1 (en) 1998-08-19 2000-03-02 North American Vaccine, Inc. Immunogenic .beta.-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
AU776828B2 (en) * 1998-12-21 2004-09-23 Medimmune, Llc Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
CN1192798C (zh) 1999-03-19 2005-03-16 史åƆäøå…‹čŽ±ę©ęƔ彻姆ē”Ÿē‰©ęœ‰é™å…¬åø ē–«č‹—
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CN201252175Y (zh) * 2008-08-04 2009-06-03 åƌ士åŗ·(ę˜†å±±)ē”µč„‘ęŽ„ę’ä»¶ęœ‰é™å…¬åø ēŗæē¼†čæžęŽ„å™Øē»„件

Also Published As

Publication number Publication date
ES2300255T3 (es) 2008-06-16
EP1880735A3 (en) 2008-03-12
DE60038166D1 (de) 2008-04-10
HUS1500040I1 (hu) 2018-05-28
HU228499B1 (en) 2013-03-28
BR0009163A (pt) 2001-12-26
US20110217329A1 (en) 2011-09-08
LU91652I9 (forum.php) 2019-01-03
US20060093626A1 (en) 2006-05-04
WO2000056359A2 (en) 2000-09-28
PT1162999E (pt) 2007-02-28
ES2275499T3 (es) 2007-06-16
CY1107390T1 (el) 2010-07-28
EP2277535A3 (en) 2011-03-09
ATE459373T1 (de) 2010-03-15
CY2009014I1 (el) 2010-07-28
JP4846906B2 (ja) 2011-12-28
PL204890B1 (pl) 2010-02-26
DK1163000T3 (da) 2008-04-28
KR100798212B1 (ko) 2008-01-24
ATE387214T1 (de) 2008-03-15
IL145044A0 (en) 2002-06-30
WO2000056358A2 (en) 2000-09-28
DE122009000054I1 (de) 2009-12-31
NZ513840A (en) 2004-02-27
AR022964A1 (es) 2002-09-04
NO330736B1 (no) 2011-06-27
MY125202A (en) 2006-07-31
PL203917B1 (pl) 2009-11-30
TWI281403B (en) 2007-05-21
DE60043930D1 (de) 2010-04-15
CN1391481A (zh) 2003-01-15
US20050031646A1 (en) 2005-02-10
PL355178A1 (en) 2004-04-05
HUP0200373A2 (en) 2002-06-29
CZ303653B6 (cs) 2013-01-30
PT1163000E (pt) 2008-03-20
US20100291138A1 (en) 2010-11-18
NZ513842A (en) 2004-05-28
CY2009014I2 (el) 2010-07-28
NO2011014I1 (no) 2011-09-19
JP2002539273A (ja) 2002-11-19
EP1162999A2 (en) 2001-12-19
EP1162999B1 (en) 2006-11-29
NL300415I1 (nl) 2009-12-01
KR20020000785A (ko) 2002-01-05
EP2277535A2 (en) 2011-01-26
CZ301445B6 (cs) 2010-03-03
NO20014322L (no) 2001-11-14
AU3291900A (en) 2000-10-09
US20030147922A1 (en) 2003-08-07
NO20014323D0 (no) 2001-09-05
TWI235064B (en) 2005-07-01
CA2366152A1 (en) 2000-09-28
CN100339130C (zh) 2007-09-26
DK1162999T3 (da) 2007-03-26
NZ513841A (en) 2001-09-28
FR10C0008I2 (fr) 2012-10-26
HK1043728B (en) 2007-06-22
LU91652I2 (fr) 2010-10-13
HK1043731B (en) 2009-01-23
NO2011014I2 (no) 2011-08-30
EP1163000A2 (en) 2001-12-19
NO20014325D0 (no) 2001-09-05
CN1351503A (zh) 2002-05-29
EP1776962A1 (en) 2007-04-25
MXPA01009452A (es) 2002-08-06
BR0009154A (pt) 2001-12-26
PL355180A1 (en) 2004-04-05
BE1025464I2 (forum.php) 2019-03-06
ES2339737T3 (es) 2010-05-25
BR0009166A (pt) 2001-12-26
PL355264A1 (en) 2004-04-05
TWI286938B (en) 2007-09-21
CN1351501A (zh) 2002-05-29
KR100642044B1 (ko) 2006-11-10
IL145045A0 (en) 2002-06-30
AU3430700A (en) 2000-10-09
BRPI0009163B8 (pt) 2021-05-25
WO2000056360A3 (en) 2001-01-25
TR200102739T2 (tr) 2001-12-21
FR10C0008I1 (fr) 2010-03-26
CN1191852C (zh) 2005-03-09
HUP0200367A2 (en) 2002-05-29
CZ20013378A3 (cs) 2002-03-13
NO20014325L (no) 2001-11-14
IL145043A0 (en) 2002-06-30
EP1162998A2 (en) 2001-12-19
KR20020000549A (ko) 2002-01-05
HU229968B1 (hu) 2015-03-30
EP1162998B1 (en) 2010-03-03
SI1163000T1 (sl) 2008-06-30
US20100119544A1 (en) 2010-05-13
BRPI0009163B1 (pt) 2019-04-09
HK1043730A1 (zh) 2002-09-27
WO2000056358A3 (en) 2001-01-04
EP1880735A2 (en) 2008-01-23
JP2002540074A (ja) 2002-11-26
CZ20013380A3 (cs) 2002-03-13
IL145043A (en) 2007-06-17
DE60032120D1 (de) 2007-01-11
SI1162999T1 (sl) 2007-04-30
EP1163000B1 (en) 2008-02-27
JP2011057713A (ja) 2011-03-24
AU3813600A (en) 2000-10-09
CN1192798C (zh) 2005-03-16
KR20020001785A (ko) 2002-01-09
JP5551579B2 (ja) 2014-07-16
AU750788B2 (en) 2002-07-25
WO2000056360A2 (en) 2000-09-28
HK1043731A1 (en) 2002-09-27
AU750913B2 (en) 2002-08-01
AR022963A1 (es) 2002-09-04
DE60032120T2 (de) 2007-09-20
CA2366314A1 (en) 2000-09-28
CA2366314C (en) 2012-01-10
DE60038166T2 (de) 2009-03-12
NO330532B1 (no) 2011-05-09
CY1107561T1 (el) 2013-03-13
TR200102735T2 (tr) 2002-04-22
HUP0200664A2 (en) 2002-06-29
CA2365296A1 (en) 2000-09-28
US20060002961A1 (en) 2006-01-05
AU750762B2 (en) 2002-07-25
TR200102736T2 (tr) 2002-04-22
AR022965A1 (es) 2002-09-04
NO20014323L (no) 2001-11-14
US20150079125A1 (en) 2015-03-19
CZ20013379A3 (cs) 2002-03-13
NO20014322D0 (no) 2001-09-05
HK1043728A1 (en) 2002-09-27
US8926985B2 (en) 2015-01-06
WO2000056359A3 (en) 2001-02-01
JP2002540075A (ja) 2002-11-26
US9168313B2 (en) 2015-10-27
MY125387A (en) 2006-07-31
IL145044A (en) 2007-03-08
ATE346608T1 (de) 2006-12-15

Similar Documents

Publication Publication Date Title
BE2018C020I2 (forum.php)
BE2015C057I2 (forum.php)
BE2016C007I2 (forum.php)
BE2015C018I2 (forum.php)
BE2014C017I2 (forum.php)
BE2013C051I2 (forum.php)
BE2013C020I2 (forum.php)
BE2013C015I2 (forum.php)
BE2013C001I2 (forum.php)
BE2012C036I2 (forum.php)
BE2008C046I2 (forum.php)
BE1025464I2 (forum.php)
BE2010C011I2 (forum.php)
JP2002514480A5 (forum.php)
BRPI0017527B8 (forum.php)
BE2008C047I2 (forum.php)
BE2011C004I2 (forum.php)
BRPI0001672A2 (forum.php)
JP2002506962A5 (forum.php)
BRPI0001542A2 (forum.php)
BRPI0012675B8 (forum.php)
BRPI0017522A2 (forum.php)
BRPI0303609A (forum.php)
BRMU7902607U2 (forum.php)
BRPI9917761A2 (forum.php)